111 related articles for article (PubMed ID: 23843564)
1. Relevant role of efflux pumps in high levels of rifaximin resistance in Escherichia coli clinical isolates.
Gomes C; Ruiz L; Pons MJ; Ochoa TJ; Ruiz J
Trans R Soc Trop Med Hyg; 2013 Sep; 107(9):545-9. PubMed ID: 23843564
[TBL] [Abstract][Full Text] [Related]
2. Fitness and molecular mechanisms of resistance to rifaximin in in vitro selected Escherichia coli mutants.
Pons MJ; Mensa L; Gascón J; Ruiz J
Microb Drug Resist; 2012 Aug; 18(4):376-9. PubMed ID: 21711150
[TBL] [Abstract][Full Text] [Related]
3. Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-β-naphthylamide-inhibitable efflux pumps.
Kothary V; Scherl EJ; Bosworth B; Jiang ZD; Dupont HL; Harel J; Simpson KW; Dogan B
Antimicrob Agents Chemother; 2013 Feb; 57(2):811-7. PubMed ID: 23183443
[TBL] [Abstract][Full Text] [Related]
4. In vitro development and analysis of Escherichia coli and Shigella boydii azithromycin-resistant mutants.
Gomes C; Pons MJ; Magallon-Tejada A; Durand D; Lluque A; Mosquito S; Riveros M; Mercado E; Prada A; Ochoa TJ; Ruiz J
Microb Drug Resist; 2013 Apr; 19(2):88-93. PubMed ID: 23176550
[TBL] [Abstract][Full Text] [Related]
5. Development of Escherichia coli rifaximin-resistant mutants: frequency of selection and stability.
Ruiz J; Mensa L; Pons MJ; Vila J; Gascon J
J Antimicrob Chemother; 2008 May; 61(5):1016-9. PubMed ID: 18325895
[TBL] [Abstract][Full Text] [Related]
6. Which mechanisms of azithromycin resistance are selected when efflux pumps are inhibited?
Gomes C; Martínez-Puchol S; Durand D; Lluque A; Mosquito S; Ochoa TJ; Ruiz J
Int J Antimicrob Agents; 2013 Oct; 42(4):307-11. PubMed ID: 23871456
[TBL] [Abstract][Full Text] [Related]
7. In vitro antimicrobial activity of rifaximin against enteropathogens causing traveler's diarrhea.
Ruiz J; Mensa L; O'Callaghan C; Pons MJ; González A; Vila J; Gascón J
Diagn Microbiol Infect Dis; 2007 Dec; 59(4):473-5. PubMed ID: 17889485
[TBL] [Abstract][Full Text] [Related]
8. Rifaximin: a review of its use in the management of traveller's diarrhoea.
Robins GW; Wellington K
Drugs; 2005; 65(12):1697-713. PubMed ID: 16060706
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of rifaximin against bacterial enteropathogens causing diarrhoea in children under 5 years of age in Ifakara, Tanzania.
Sierra JM; Navia MM; Vargas M; Urassa H; Schellemberg D; Gascón J; Vila J; Ruiz J
J Antimicrob Chemother; 2001 Jun; 47(6):904-5. PubMed ID: 11389133
[No Abstract] [Full Text] [Related]
10. Rifamycin inhibition of WT and Rif-resistant Mycobacterium tuberculosis and Escherichia coli RNA polymerases in vitro.
Gill SK; Garcia GA
Tuberculosis (Edinb); 2011 Sep; 91(5):361-9. PubMed ID: 21704562
[TBL] [Abstract][Full Text] [Related]
11. In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas.
Jiang ZD; DuPont HL; La Rocco M; Garey KW
J Clin Pathol; 2010 Apr; 63(4):355-8. PubMed ID: 20354207
[TBL] [Abstract][Full Text] [Related]
12. Effect of 1-(1-naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of Escherichia coli.
Kern WV; Steinke P; Schumacher A; Schuster S; von Baum H; Bohnert JA
J Antimicrob Chemother; 2006 Feb; 57(2):339-43. PubMed ID: 16354747
[TBL] [Abstract][Full Text] [Related]
13. In vitro antimicrobial susceptibility of bacterial enteropathogens isolated from international travelers to Mexico, Guatemala, and India from 2006 to 2008.
Ouyang-Latimer J; Jafri S; VanTassel A; Jiang ZD; Gurleen K; Rodriguez S; Nandy RK; Ramamurthy T; Chatterjee S; McKenzie R; Steffen R; DuPont HL
Antimicrob Agents Chemother; 2011 Feb; 55(2):874-8. PubMed ID: 21115800
[TBL] [Abstract][Full Text] [Related]
14. Rifaximin-induced alteration of virulence of diarrhoea-producing Escherichia coli and Shigella sonnei.
Jiang ZD; Ke S; Dupont HL
Int J Antimicrob Agents; 2010 Mar; 35(3):278-81. PubMed ID: 20045287
[TBL] [Abstract][Full Text] [Related]
15. Multidrug efflux inhibition in Acinetobacter baumannii: comparison between 1-(1-naphthylmethyl)-piperazine and phenyl-arginine-beta-naphthylamide.
Pannek S; Higgins PG; Steinke P; Jonas D; Akova M; Bohnert JA; Seifert H; Kern WV
J Antimicrob Chemother; 2006 May; 57(5):970-4. PubMed ID: 16531429
[TBL] [Abstract][Full Text] [Related]
16. [Investigation of the effect of efflux pump inhibitors to MIC values of ciprofloxacin in clinical isolates of Pseudomonas aeruginosa, Escherichia coli, Acinetobacter baumannii and Staphylococcus aureus].
Cetinkaya E; Coban AY; Durupinar B
Mikrobiyol Bul; 2008 Oct; 42(4):553-61. PubMed ID: 19149076
[TBL] [Abstract][Full Text] [Related]
17. Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections.
Cottreau J; Baker SF; DuPont HL; Garey KW
Expert Rev Anti Infect Ther; 2010 Jul; 8(7):747-60. PubMed ID: 20586560
[TBL] [Abstract][Full Text] [Related]
18. Synergistic Actions of Benzyl Isothiocyanate with Ethylenediaminetetraacetic Acid and Efflux Pump Inhibitor Phenylalanine-Arginine β-Naphthylamide Against Multidrug-Resistant
Lin KH; Lo CC; Chou MC; Yeh TH; Chen KL; Liao WY; Lo HR
Microb Drug Resist; 2020 May; 26(5):468-474. PubMed ID: 31755808
[TBL] [Abstract][Full Text] [Related]
19. Effects of rifaximin on bacterial virulence mechanisms at supra- and sub-inhibitory concentrations.
Debbia EA; Maioli E; Roveta S; Marchese A
J Chemother; 2008 Apr; 20(2):186-94. PubMed ID: 18467244
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity and fecal concentration of rifaximin after oral administration.
Jiang ZD; Ke S; Palazzini E; Riopel L; Dupont H
Antimicrob Agents Chemother; 2000 Aug; 44(8):2205-6. PubMed ID: 10898704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
